Medication info
Ritamezin Tablet 2.5/1000 mg

Ritamezin Tablet 2.5/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Kyungdong Pharmaceutical Co., Ltd.
Appearance
Bright pink, double-convex, oval film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 201803144 · Approved 2018.07.30 · Insurance code 648104110

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). 5. Patients who do not achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), provided they have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. The starting dose of metformin is 500mg or 850mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Kyungdong Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes. It helps effectively manage blood sugar by administering Linagliptin and Metformin together, especially in patients who are also following dietary and exercise programs. This helps maintain stable blood sugar levels and contributes to the prevention of complications. Taking this medication in conjunction with improvements in lifestyle can greatly aid diabetes management. Therefore, this medication improves blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients who do not achieve adequate glycemic control with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients who do not achieve adequate glycemic control with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). 5. Patients who do not achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), provided they have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. The starting dose of metformin is 500mg or 850mg once daily; therefore, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication may cause a very rare side effect known as lactic acidosis, which can be more dangerous in cases of rapidly deteriorating renal function or issues with the heart or lungs. Patients with allergies to the active ingredients or components of this drug, those with type 1 diabetes, lactic acidosis, diabetic ketoacidosis, severe renal impairment, liver dysfunction, acute alcohol intoxication, as well as those who are pregnant or breastfeeding should not use this medication. Caution is required when using this drug in combination with other blood sugar-lowering medications as there is a risk of hypoglycemia, especially when used with insulin or sulfonylureas, as dosage adjustments may be necessary. Patients with weakened renal function or elderly patients should regularly undergo renal function tests and should not use this drug if renal function drops below a certain standard. Patients with poor cardiac function should also exercise caution when using this medication, and symptoms such as acute pancreatitis or bullous pemphigoid skin conditions may occur, necessitating immediate consultation with a doctor if they arise. This medication can lower vitamin B12 levels, so it is advisable to monitor vitamin B12 status through blood tests during long-term use. If iodine contrast agents used in radiological examinations are administered, this medication should be discontinued for a period before and after the test, and it should also be suspended around the time of surgery. Women who are pregnant or planning to become pregnant should preferably avoid using this medication, and it should also be avoided during breastfeeding. Use in children under 10 years of age and adolescents aged 10 to 17 is not recommended as safety and efficacy have not been adequately established. Overdose poses a significant risk of lactic acidosis, so if any abnormal symptoms appear, medical attention should be sought immediately, and blood dialysis may be necessary. This medication should be stored out of reach of children, away from moisture, and should not be transferred to other containers.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disorder
  • cough
  • appetite loss
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 94 more
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • bullous pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 reduction and deficiency
  • oral ulcers
  • fever
  • facial edema
  • fatigue
  • constipation
  • upper abdominal pain
  • enterocolitis
  • bowel obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • dizziness
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • contusions
  • bone contusions
  • concussion
  • meniscal injury
  • bone fracture
  • hand fracture
  • pneumoconiosis
  • lacerations
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hearing loss
  • erectile dysfunction
  • goiter
  • kidney transplant failure
  • anemia
  • dizziness
  • sensory loss
  • itching
  • hypertension
  • benign prostatic hyperplasia
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • altered mental status
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is also advisable to store the medication at room temperature, avoiding places that are too hot or too cold, ideally between 1°C and 30°C.

Appearance and packaging

Appearance

Bright pink, double-convex, oval film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.